Lifeward Ltd

Lifeward Ltd (LFWD) Stock Analysis

$7.460

+0.096 (+1.29%)At close

Loading chart…
High
7.500
Open
7.300
VWAP
7.39
Vol
4.41K
Mkt Cap
Low
7.200
Amount
32.57K
EV/EBITDA, TTM
-0.67

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

AI analysis of Lifeward Ltd (LFWD)

buy

ReWalk Robotics Ltd appears to be a good buy right now, primarily due to its current price of $7.46, which is significantly below the analyst price target of $10, indicating a potential upside of 34%. Additionally, the company's recent revenue growth of 11% year-over-year in ReWalk personal exoskeleton sales suggests positive momentum. However, investors should be cautious of the high net loss of $11.5 million reported in Q2 2026, which represents a risk to profitability.

Valuation Metrics

The current forward P/E ratio for Lifeward Ltd (LFWD) is 0.00, compared to its 5-year average forward P/E of -3.13.

Forward P/E

Overvalued
5Y Average P/E
-3.13
Current P/E
0.00
Overvalued
-1.37
Undervalued
-4.90

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
-0.04
Current EV/EBITDA
-0.67
Overvalued
0.51
Undervalued
-0.60

Forward P/S

Fair
5Y Average P/S
2.93
Current P/S
0.50
Overvalued
6.52
Undervalued
-0.66

Alphio AI Price Scenarios for LFWD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%LFWD

$1.83

Scenario price

B

Base

Base · 50%LFWD

$1.53

Scenario price

B

Bear

Bear · 25%LFWD

$1.30

Scenario price

Events Timeline

2026-08-03 (ET)

09:30:00

Company Not Selling 2.07M Ordinary Shares

2026-05-19 (ET)

08:30:00

Lifeward Appoints Keith Rose as Chief Medical Officer

2026-04-27 (ET)

17:10:00

Lifeward Files to Sell 7.26M Ordinary Shares

2026-03-25 (ET)

16:50:00

Lifeward Closes Strategic Partnership with Oramed

2026-03-18 (ET)

08:10:00

Lifeward Reports Q4 Revenue of $5.1M, CEO Highlights Strategic Investment

News

LFWD FAQ — answered by Alphio AI

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

ReWalk Robotics Ltd appears to be a good buy right now, primarily due to its current price of $7.46, which is significantly below the analyst price target of $10, indicating a potential upside of 34%. Additionally, the company's recent revenue growth of 11% year-over-year in ReWalk personal exoskeleton sales suggests positive momentum. However, investors should be cautious of the high net loss of $11.5 million reported in Q2 2026, which represents a risk to profitability.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started